Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings ...

Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 ...

US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...

The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain muscle integrity compared with control.

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...

Regenxbio (RGNX) stock gains and Solid Biosciences (SLDB) stock falls after Sarepta Therapeutics' (SRPT) safety update on ...

Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The company’s shares closed yesterday at $7.00. Easily identify ...

In a report released on March 14, Luca Issi from RBC Capital maintained a Buy rating on RegenXBio (RGNX – Research Report), with a price target of $30.00. The company’s shares ...

We feel now is a pretty good time to analyse REGENXBIO Inc.'s ( NASDAQ:RGNX ) business as it appears the company may ...

US biotech Regenxbio (Nasdaq: RGNX) has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) ...